Trial Profile
A phase Ib trial to evaluate the efficacy and safety of buparlisib plus letrozole in patients with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SU2C
- 11 Feb 2016 New trial record
- 12 Dec 2015 Results (n=33) presented at the 38th Annual San Antonio Breast Cancer Symposium.